| Lidocaine Hydrochloride Imp. H (EP): 2-Chloro-N-(2,6-dimethylphenyl)- acetamide | 1131-01-7 | C10H12ClNO |
| Lidocaine Hydrochloride Imp. I (EP) as Hydrochloride: 2-(Diethylamino)- N-(2,4-dimethylphenyl)acetamide Hydrochloride | 17289-54-2 | C14H23ClN2O |
| Lidocaine Hydrochloride Imp. J (EP) as Hydrochloride: 2-(Diethylamino)- N-(2,5-dimethylphenyl)acetamide Hydrochloride | 1012864-23-1 | C14H23ClN2O |
| Lidocaine Hydrochloride Imp. K (EP) as Hydrochloride: N-(2,6-Dimethyl- phenyl)-2-(ethylmethylamino)acetamide Hydro- chloride | 50295-20-0 | C13H21ClN2O |
| Lidocaine Impurity 2 | 1596965-85-3 | C11H23N3O2 |
| Lidocaine Impurity 4 | 219500-63-7 | C10H13NS2 |
| Lidocaine Impurity 5 | 2903-48-2 | C10H11NO3 |
| Lidocaine Impurity 6 HCl | 857170-05-9 | C14H23ClN2O |
| Lidocaine Impurity 7 HCl | 77966-82-6 | C14H23ClN2O |
| Lidocaine Impurity 8 | 2315-36-8 | C6H12ClNO |
| Lidocaine Impurity 9 | 1606-01-5 | C6H13NO2 |
| Lidocaine Impurity 13 | 5177-35-5 | C10H12ClNO |
| Lidocaine Impurity 17 | 1131-01-7 | C10H12ClNO |
| Lidocaine Impurity F | 857170-72-0 | C14H23ClN2O |
| Lidocaine Impurity G | Not available | C13H21ClN2O |
| Lidocaine N-Oxide (2-(Diethyloxidoamino)-N-(2,6-dimethylphenyl)acetamide) | 2903-45-9 | C14H22N2O2 |
| Lidocaine Related Compound A | 87-62-7 | C8H11N |
| Lidocaine Related Compound C | 2198-53-0 | C10H13NO |
| Lidocaine Related Compound H | 1131-01-7 | C10H12ClNO |
| Lifitegrast | 1025967-78-5 | C29H24Cl2N2O7S |
| Lifitegrast Impurity 2 | 1194550-65-6 | C27H27Cl3N2O5S |
| Lifitegrast Impurity 3 | 2295862-29-0 | C30H26Cl2N2O7S |
| Lifitegrast Impurity 4 | 1194550-67-8 | C36H30Cl2N2O7S |
| Lifitegrast Impurity 5 | 1289646-93-0 | C10H10Cl3NO2 |
| Lifitegrast Impurity 8 | 2271299-08-0 | C29H24Cl2N2O7S |
| Lifitegrast Impurity 9 | 166599-84-4 | C9H6O3 |
| Lifitegrast Impurity 10 | 90484-22-3 | C9H6O3 |
| Lifitegrast Impurity 11 | 77095-51-3 | C9H6O3 |
| Lifitegrast Impurity 12 | 2295862-00-7 | C29H26N2O7S |
| Lifitegrast Impurity 14 | 2295862-24-5 | C31H28Cl2N2O7S |
| Lifitegrast Impurity 15 | 2049127-88-8 | C17H20ClNO4S |
| Lifitegrast Impurity 18 | 1270093-99-6 | C10H13NO4S |
| Lifitegrast Impurity 19 | 1290176-71-4 | C10H9Cl2NO2 |
| Lifitegrast Impurity 20 | 2129597-34-6 | C19H13Cl2NO4 |
| Lifitegrast Impurity 22 | 90721-27-0 | C9H6O3 |
| Lifitegrast Impurity 23 | 2271054-95-4 | C20H21Cl3N2O5S |
| Lifitegrast Impurity 24 | 1289646-72-5 | C28H23Cl2N |
| Lifitegrast Impurity 25 | 851785-70-1 | C20H20Cl2N2O5S |
| Lifitegrast Impurity 29 | 2322380-18-5 | C29H25ClN2O7S |
| Lifitegrast Impurity 30 | 2322380-15-2 | C29H25ClN2O7S |
| Lifitegrast Impurity 32 | 1289646-90-7 | C11H10O3 |
| Lifitegrast Impurity 33 | 2049127-84-4 | C11H16ClNO4S |
| Lifitegrast Impurity 36 | 73075-47-5 | C9H10Cl3N |
| Lifitegrast Impurity 37 | 82278-73-7 | C14H18BrNO4 |
| Lifitegrast Impurity 39 | 2049127-86-6 | C10H14ClNO4S |
| Lifitegrast Impurity 40 | 851784-82-2 | C15H17Cl2NO4 |
| Lifitegrast Impurity 41 | 14046-52-7 | C9H11Cl4N |
| Lifitegrast Impurity 45 | 170097-67-3 | C15H19NO4 |
| Lifitegrast Impurity 46 | 2605229-68-1 | C15H18ClNO4 |
| Lifitegrast Impurity 49 | 1865726-28-8 | C17H19NO4S |
| Lifitegrast Impurity 51 | 2177264-60-5 | C10H14ClNO4S |
| Lifitegrast Impurity 52 | 2762168-17-0 | C25H28Cl2N2O7S |
| Lifitegrast Impurity 59 | 1194550-61-2 | C32H34Cl2N2O7S |
| Lignan P | 23363-35-1 | C27H30O13 |
| Lignan P Phosphate | Not available | C27H31O16P |
| Lignoceric acid methyl ester | 2442-49-1 | C25H50O2 |
| Limapros | 74397-12-9 | C22H36O5 |
| Linagliptin Acetamide | 1803079-49-3 | C27H30N8O3 |
| Linagliptin impurity 1 | 2138805-26-0 | C25H29ClN8O2 |
| Linagliptin impurity 2 | 1418133-47-7 | C16H11N3O4S |
| Linagliptin Impurity 3 | 2138392-83-1 | C26H21BrN8O2 |
| Linagliptin impurity 3 | 2428491-17-0 | C16H13BrN6O2 |
| Linagliptin impurity 4 | 1573118-33-8 | C34H32N8O4 |
| Linagliptin impurity 5 | 2137744-33-1 | C26H28N8O3 |
| Linagliptin impurity 6 | 1446263-39-3 | C25H29BrN8O2 |
| Linagliptin impurity 7 | 1638744-06-5 | C25H29BrN8O2 |
| Linagliptin impurity 9 | 1803079-49-3 | C27H30N8O3 |
| Linagliptin impurity 10 | 586408-08-4 | C10H10N4O2 |
| Linagliptin impurity 11 | 1911621-52-7 | C20H18N6O2 |
| Linagliptin impurity 15 | 1955514-80-3 | C26H29N9O3 |
| Linagliptin impurity 17 | 886588-63-2 | C33H30N8O4 |
| Linagliptin impurity 18 | 2074688-84-7 | C22H23N7O3 |
| Linagliptin impurity 19 | 2803370-12-7 | C38H42N10O4 |
| Linagliptin impurity 23 | 2463617-43-6 | C25H28N8O2 |
| Linagliptin impurity 31 | 188111-79-7 | C10H20N2O2 |
| Linagliptin impurity 34 | 2443735-53-1 | C38H42N10O4 |
| Linagliptin Impurity 37 | 666816-98-4 | C10H9BrN4O2 |
| Linagliptin Impurity 66 | 2434-53-9 | C5H7N3O2 |
| Linagliptin Impurity A | 853029-57-9 | C20H17BrN6O2 |
| Linagliptin Impurity B | 668273-75-4 | C30H36N8O4 |
| Linagliptin Impurity D | 666816-91-7 | C20H28N6O4 |
| Linagliptin Impurity F | 1673546-62-7 | C27H27F3N8O3 |
| Linagliptin Impurity G | 668270-11-9 | C25H28N8O2 |
| Linagliptin Impurity I | 2749405-42-1 | C16H13BrN6O2 |
| Linagliptin Impurity M | 2436762-89-7 | C14H13BrN4O2 |
| Linagliptin Impurity P | 1791405-13-4 | C15H20N6O2 |
| Linagliptin Impurity T | 2416949-69-2 | C25H29N7O4 |
| Linalol | 78-70-6 | C10H18O |
| Linarin | 480-36-4 | C28H32O14 |
| Linarine | 480-36-4 | C28H32O14 |
| Lincomycin 2-Phosphate | Not available | C18H35N2O9PS |
| Lincomycin EP Impurity C | 2256-16-8 | C17H32N2O6S |
| Lincomycin EP Impurity C HCl | 14600-41-0 | C17H33ClN2O6S |
| Lincomycin EP Impurity D | 17017-22-0 | C18H34N2O6S |
| Lincomycin EP Impurity D HCl | 26389-84-4 | C18H35ClN2O6S |
| Lincomycin EP Impurity E | 13380-36-4 | C9H17NO2 |
| Lincomycin EP Impurity E HCl | 6734-79-8 | C9H18ClNO2 |
| Lincomycin EP Impurity F | 14810-93-6 | C9H19NO5S |
| Lincomycin hydrochloride for system suitability | 7179-49-9 | C18H37ClN2O7S |
| Lincomycin impurity 2 | 2520-24-3 | C17H32N2O6S |
| Lincomycin palmitate | 23295-14-9 | C34H65ClN2O7S |
| Lindane Related Compound A | 319-84-6 | C6H6Cl6 |
| Linear Daptomycin Hydrochloride Salt | Not available | C72H104ClN17O27 |
| Linezolid <I>R</I>-Isomer | 872992-20-6 | C16H20FN3O4 |
| Linezolid Dimer | 908143-04-4 | C30H35F2N5O7 |
| Linezolid impurity 1 | 872992-20-6 | C16H20FN3O4 |
| Linezolid impurity 3 | 556801-15-1 | C16H21N3O4 |
| Linezolid impurity 4 | 189038-36-6 | C16H20FN3O5 |
| Linezolid impurity 5 | 851379-25-4 | C14H19ClFN3O3 |
| Linezolid impurity 6 | 333753-67-6 | C15H22FN3O3 |
| Linezolid impurity 7 | 168828-81-7 | C18H19FN2O3 |
| Linezolid impurity 8 | 868405-66-7 | C13H18ClFN2O2 |
| Linezolid impurity 9 | 216868-57-4 | C16H20FN3O3S |
| Linezolid impurity 10 | 496031-56-2 | C16H19FN2O5 |
| Linezolid impurity 11 | 174649-09-3 | C15H19FN2O6S |
| Linezolid impurity 12 | 168828-89-5 | C22H20FN3O5 |
| Linezolid impurity 15 | 1666111-39-2 | C16H19N3O5 |
| Linezolid impurity 19 | 2512211-93-5 | C15H20FN3O2 |
| Linezolid Impurity 19 | 168828-90-8 | C14H18FN3O3 |
| Linezolid impurity 20 | 908143-04-4 | C30H35F2N5O7 |
| Linezolid impurity 21 | 333753-69-8 | C15H22FN3O3 |
| Linezolid Impurity 22 | 93246-53-8 | C10H13FN2O |
| Linezolid impurity 22 | 333753-71-2 | C15H22FN3O3 |
| Linezolid impurity 23 | 1391068-25-9 | C15H23ClFN3O3 |
| Linezolid impurity 24 | 168828-82-8 | C14H17FN2O4 |
| Linezolid impurity 29 | 2055572-73-9 | C15H23ClFN3O3 |
| Linezolid impurity 31 | 1391062-33-1 | C15H20FN3O2 |
| Linezolid impurity 32 | 1394245-06-7 | C16H22FN3O5 |
| Linezolid N-Oxide | 189038-36-6 | C16H20FN3O5 |
| Linezolid R-Isomer | 872992-20-6 | C16H20FN3O4 |
| Linezolid Related Compound A | 168828-84-0 | C14H16FN5O3 |
| Linezolid Related Compound B | 216868-57-4 | C16H20FN3O3S |
| Linezolid Related Compound C | 168828-90-8 | C14H18FN3O3 |
| Linezolid Related Compound D | 174649-09-3 | C15H19FN2O6S |
| Linezolid USP Related Compound A | 168828-84-0 | C14H16FN5O3 |
| Linolenic acid ethyl ester | 1191-41-9 | C20H34O2 |
| Linzagoli impurity 1 | 935283-04-8 | C22H15F3N2O7S |
| Linzagoli impurity 2 | 2218504-94-8 | C7H6FNO4 |
| Linzagoli impurity 3 | 1033103-05-7 | C7H8FNO2 |
| Linzagoli impurity 4 | 2168201-68-9 | C6H6FNO2 |
| Liothyronine Ethyl Ester | 3005-97-8 | C17H16I3NO4 |
| Liothyronine for peak identification | 55-06-1 | C15H11I3NNaO4 |
| Liothyronine Isopropyl Ester | Not available | C18H18I3NO4 |
| Liothyronine Methyl Ester | 54914-53-3 | C16H14I3NO4 |
| Liothyronine Sodium Imp. C (EP): [4-(4-Hydroxy-3-iodophenoxy)-3,5- | 51-24-1 | C14H9I3O4 |
| Liothyronine Sodium Imp. E (EP): (2S)-2-Amino-3-[4-(4-hydroxyphenoxy)-3,5- | 1041-01-6 | C15H13I2NO4 |
| Lisdexamfetamine Dimesylate | 608137-33-3 | C17H33N3O7S2 |
| Lisinopril (8R,S)-Diketopiperazine (Mixture of Diastereomers) | 1092813-99-4 | C21H29N3O4 |
| Lisinopril (8R,S)-Diketopiperazine (Mixture of Diastereomers)Mps1-IN-1 dihydrochloride | 1092813-99-4 | C21H29N3O4 |
| Lisinopril Cyclohexyl Analogue | 1132650-67-9 | C21H37N3O5 |
| Lisinopril Dihydrate Imp. A (EP): (2RS)-2-Amino-4-phenylbutanoic Acid | 1012-05-1 | C10H13NO2 |
| Lisinopril Dihydrate Imp. B (EP) as Hydrate: 4-Methylbenzene- sulphonic Acid Hydrate | 6192-52-5 | C7H10O4S |
| Lisinopril Dihydrate Imp. C (EP): (2S)-2-[(3S,8aS)-3-(4-Aminobutyl)- 1,4-dioxohexahydropyrrolo[1,2-a]pyrazin-2(1H)- yl]-4-phenylbutanoic Acid (S,S,S-Diketopiperazine) | 328385-86-0 | C21H29N3O4 |
| Lisinopril Dihydrate Imp. D (EP): (2S)-2-[(3S,8aR)-3-(4-Aminobutyl)- 1,4-dioxohexahydropyrrolo[1,2-a]pyrazin-2(1H)- yl]-4-phenylbutanoic Acid (R,S,S-Diketopiperazine) | 219677-82-4 | C21H29N3O4 |
| Lisinopril Diketopiperazine | 219677-82-4 | C21H29N3O4 |
| Lisinopril EP Impurity A | 1012-05-1 | C10H13NO2 |
| Lisinopril EP Impurity C | 328385-86-0 | C21H29N3O4 |
| Lisinopril EP Impurity D | 219677-82-4 | C21H29N3O4 |
| Lisinopril EP Impurity E | 85955-59-5 | C21H31N3O5 |
| Lisinopril EP Impurity F | 1132650-67-9 | C21H37N3O5 |
| Lisinopril EP Impurity H | 138247-43-5 | C16H24N2O4 |
| Lisinopril EP Impurity J | 2566937-60-6 | C37H53N5O8 |
| Lisinopril for system suitability A | 83915-83-7 | C21H35N3O7 |
| Lisinopril Impurity 2 | Not available | C37H53N5O8 |
| Lisinopril Impurity A | 1012-05-1 | C10H13NO2 |
| Lisinopril Impurity B | 6192-52-5 | C7H10O4S |
| Lisinopril impurity F | 1132650-67-9 | C21H37N3O5 |
| Lisinopril R,S,S-Diketopiperazine | 1092813-99-4 | C21H29N3O4 |
| Lisinopril Related Compound A | 328385-86-0 | C21H29N3O4 |
| Lithocholic Acid 3-O-Glucuronide | 75239-91-7 | C30H48O9 |
| LMP744 | 308246-52-8 | C24H24N2O7 |
| Lobeline | 90-69-7 | C22H27NO2 |
| Lobeline EP Impurity B | 579-21-5 | C22H25NO2 |
| Lobeline hydrochloride impurity intermediate B | 614-20-0 | C9H8O3 |
| Lobeline hydrochloride impurity starting material B | 94-02-0 | C11H12O3 |
| Lobeline impurity 2 | 246018-80-4 | C22H27NO2 |
| Lobellin hydrochloride impurity diastereomersD | 686709-76-2 | C22H27NO2 |
| Lodoxamide Impurity 1 | 61313-43-7 | C7H4N4O4 |
| Lodoxamide Impurity 2 | 34207-46-0 | C7H6ClN3 |
| Lodoxamide Impurity 4 | 53882-13-6 | C15H14ClN3O6 |
| Lodoxamide Impurity 7 | 84944-23-0 | C9H6ClN3O3 |
| Lodoxamide Impurity 9 | 53882-26-1 | C11H7ClN2O8 |
| Lodoxamide Monomer | 53882-12-5 | C11H6ClN3O6 |
| Lombartinib impurity2 | 1069122-99-1 | C7H7ClN2O2 |
| Lomitapide Impurity 1 | 182439-11-8 | C20H18F3NO3 |
| Lomustine EP impurity C | 2387-23-7 | C13H24N2O |
| Lomustine Imp. B (EP): 1-(2-Chloroethyl)-3-cyclohexylurea | 13908-11-7 | C9H17ClN2O |
| Lomustine Imp. C (EP): 1,3-Dicyclohexylurea | 2387-23-7 | C13H24N2O |
| Lomustine Related Compound B | 13908-11-7 | C9H17ClN2O |
| Lomustine Related Compound B (1-(2- Chloroethyl)-3-cyclohexylurea) | Not available | C9H17ClN2O |
| Lomustine Related Compound D | 54749-91-6 | C9H16ClN3O2 |
| Loperamide | 53179-11-6 | C29H33ClN2O2 |
| Loperamide <I>N</I>-oxide | 106900-12-3 | C29H33ClN2O3 |
| Loperamide EP Impurity A | 1391052-94-0 | C35H37ClN2O2 |
| Loperamide EP Impurity C | 39512-49-7 | C11H14ClNO |
| Loperamide EP Impurity D | 37743-41-2 | C29H34N2O2 |
| Loperamide EP Impurity E | 1426322-82-8 | C38H40Cl2N2O3 |
| Loperamide EP Impurity F | 106900-12-3 | C29H33ClN2O3 |
| Loperamide EP Impurity G | 109572-89-6 | C29H33ClN2O3 |
| Loperamide EP Impurity H | 61299-42-1 | C29H31ClN2O |
| Loperamide for system suitability | 34552-83-5 | C29H34Cl2N2O2 |
| Loperamide Hydrochloride Imp. A (EP): 4-[4-(4'-Chlorobiphenyl-4-yl)-4- hydroxypiperidin-1-yl]-N,N-dimethyl-2,2- diphenylbutanamide | 1391052-94-0 | C35H37ClN2O2 |
| Loperamide Hydrochloride Imp. C (EP): 4-(4-Chlorophenyl)piperidin-4-ol | 39512-49-7 | C11H14ClNO |
| Loperamide Hydrochloride Imp. D (EP): 4-(4-Hydroxy-4-phenylpiperidin- 1-yl)-N,N-dimethyl-2,2-diphenylbutanamide | 37743-41-2 | C29H34N2O2 |
| Loperamide Hydrochloride Imp. F (EP): Loperamide Oxide | 106900-12-3 | C29H33ClN2O3 |
| Loperamide Impurity 4 | 37743-18-3 | C18H20BrNO |
| Loperamide N-oxide | 106900-12-3 | C29H33ClN2O3 |
| Loperamide oxide monohydrate | 106900-12-3 | C29H33ClN2O3 |
| Loperamide Related Compound F | 106900-12-3 | C29H33ClN2O3 |
| Loperamide-D6 HCl | 1189469-46-2 | C29H34Cl2N2O2 |
| Lopinavir D-Valine Diastereomer | 1623021-24-8 | C37H48N4O5 |
| Lopinavir EP Impurity A | 192726-05-9 | C27H38N4O3 |
| Lopinavir EP Impurity B | Not available | C28H38N4O4 |
| Lopinavir EP Impurity C | Not available | C36H52N6O5 |
| Lopinavir EP Impurity D | Not available | C37H48N4O8S |
| Lopinavir EP Impurity E | 192725-49-8 | C28H34N2O3 |
| Lopinavir EP Impurity F | Not available | C29H34N2O4 |
| Lopinavir EP Impurity G | Not available | C30H36N2O4 |
| Lopinavir EP Impurity H | Not available | C29H32N2O4 |
| Lopinavir EP Impurity I | Not available | C37H48N4O5 |
| Lopinavir EP Impurity J | Not available | C37H48N4O5 |
| Lopinavir EP Impurity K | 1623021-24-8 | C37H48N4O5 |
| Lopinavir EP Impurity L | Not available | C22H26N2O4 |
| Lopinavir EP Impurity N | 1798014-18-2 | C37H48N4O5 |
| Lopinavir EP Impurity P | 1217628-64-2 | C37H48N4O5 |
| Lopinavir EP Impurity Q | 667904-94-1 | C38H44N2O5 |
| Lopinavir EP Impurity R | 943250-66-6 | C47H58N4O7 |
| Lopinavir EP Impurity S | 943250-65-5 | C47H58N4O7 |
| Lopinavir EP Impurity T | 1797024-56-6 | C57H66N4O7 |
| Lopinavir EP-T Impurity | 1797024-56-6 | C57H66N4O7 |
| Lopinavir for peak identification | 192725-17-0 | C37H48N4O5 |
| Lopinavir for system suitability | 192725-17-0 | C37H48N4O5 |
| Lopinavir Impurity 23 | 357275-54-8 | C37H48N4O6 |
| Lopinavir Intermediate 2 | 192726-06-0 | C32H45N5O6 |
| Lopinavir IP Impurity E (Impurity 22) | 192725-39-6 | C37H46N4O6 |
| Lopinavir metabolite M-1 | 192725-39-6 | C37H46N4O6 |
| Lopinavir N2,N5-(2,6-Xylyloxy)acetyl Impurity | Not available | C38H44N2O5 |
| Lopinavir N2,N5-(2,6-Xylyloxy)acetyl Impurity-d9 | Not available | C38H44N2O5 |
| Lopinavir N2,N5-Divalinate Impurity | Not available | C36H52N6O5 |
| Lopinavir N2,N5-Divalinate Impurity-d8 | Not available | C36H52N6O5 |
| Lopinavir-D8 | 1224729-35-4 | C37H48N4O5 |
| Loratadine EP Impurity A | 133284-74-9 | C22H25ClN2O3 |
| Loratadine EP Impurity B | 31251-41-9 | C14H10ClNO |
| Loratadine EP Impurity C | 165739-83-3 | C22H22Cl2N2O2 |
| Loratadine EP Impurity F | 125743-80-8 | C22H24ClFN2O2 |
| Loratadine EP Impurity G | 38092-89-6 | C20H21ClN2 |
| Loratadine Epoxide | 1189694-51-6 | C22H23ClN2O3 |
| Loratadine Epoxide N-Oxide | 1432057-93-6 | C22H23ClN2O4 |
| Loratadine for system suitability | 79794-75-5 | C22H23ClN2O2 |
| Loratadine Imp. B (EP): 8-Chloro-5,6-dihydro-11H- benzo[5.6]cyclohepta[1,2-b]pyridin-11-one | 31251-41-9 | C14H10ClNO |
